Kaisa Health Group Holdings Limited (0876) AI Stock Analysis

• Market Cap: HK$983.22M
• Dividend Yield: N/A
• Average Volume (3M): 76.64M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.32
• Revenue Growth: -8.46%
• EPS Growth: 45.13%
• Country: HK
• Employees: 861
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Instruments & Supplies
• EPS (TTM): >-0.01
• Shares Outstanding: 5,042,139,000
• 10 Day Avg. Volume: 53,429,215
• 30 Day Avg. Volume: 76,644,739
• PEG Ratio: <0.01
• Price to Book (P/B): 0.28
• Price to Sales (P/S): 0.65
• P/FCF Ratio: -3.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: HK$0.17 ▲(88.89% Upside)
• Action: Reiterated Date: 01/15/26
• Date: Action: Reiterated 01/15/26

The score is held back primarily by weak financial performance (ongoing losses and poor operating/free cash flow), with only partial support from a low-leverage, cash-backed balance sheet. Technicals are strong but appear overbought, and valuation support is limited due to losses and no dividend data.

Positive Factors

Low leverage and liquidity buffer

A very low debt load and cash exceeding debt provide durable financial flexibility: the company can fund operations, endure revenue shortfalls, or pursue strategic investments without urgent refinancing. This reduces solvency risk and supports multi-quarter resilience.

High equity ratio / capitalization

An equity ratio above 80% signals strong capitalization, creating a long-term buffer against losses. This enhances creditworthiness and lowers bankruptcy risk, allowing management to take measured strategic actions without immediate pressure from creditors.

Stable gross profit margins

Relatively stable gross margins indicate the core product mix retains unit-level profitability. If revenue growth resumes, stable gross margins allow operating leverage to improve margins and profitability over several quarters, supporting sustainable margin recovery.

Negative Factors

Persistent net losses

Ongoing net losses erode equity and limit reinvestment capacity. Over months, sustained deficits can force dilutive capital raises or spending cuts, undermining long-term strategic initiatives and making a durable path to profitability imperative for viability.

Weak operating cash generation

Inability to generate positive operating cash flow means the business isn't converting revenues into cash, raising reliance on financing to fund operations. Structurally, this limits capacity for capex, R&D, or expansion without external capital over the coming quarters.

Eroding asset base and equity

Declining assets and shareholder equity shrink the balance-sheet cushion against shocks and reduce borrowing capacity. Over several quarters, this trend can impair scale, limit strategic options, and signal structural contraction rather than temporary fluctuation.

Kaisa Health Group Holdings Limited Business Overview & Revenue Model

Company Description

Kaisa Health Group Holdings Limited, an investment holding company, manufactures and trades in dental prosthetics in the People's Republic of China and internationally. The company offers dental prosthetics, including crowns and bridges, removable full and partial dentures, implants, and full-cast restorations, as well as provides public health and medical services. It is also involved in the investment holding of convertible bonds, as well as provision of medical technology and health care project development, medical consultation, and other medical services. The company was formerly known as Mega Medical Technology Limited and changed its name to Kaisa Health Group Holdings Limited in January 2018. Kaisa Health Group Holdings Limited was founded in 1971 and is headquartered in Central, Hong Kong.

How the Company Makes Money

Kaisa Health Group Holdings Limited generates revenue through several key streams. Primarily, the company earns income from the sale of health supplements and wellness products, which are marketed through various retail and online channels. Additionally, Kaisa Health provides medical services, including consultations and health management programs, which contribute to its revenue. The company may also engage in partnerships with healthcare providers and distributors, enhancing its market reach and operational efficiency. Significant collaborations with hospitals or health institutions could further bolster revenue, while the growing demand for health and wellness solutions in Asia presents opportunities for expansion and increased profitability.

Kaisa Health Group Holdings Limited Financial Statement Overview

Summary

Weak fundamentals driven by persistent net losses and poor cash generation (operating cash flow was zero in 2024, with negative free cash flow in prior years). The balance sheet is a partial offset with low leverage and cash exceeding debt, but declining assets and equity raise longer-term stability concerns.

Income Statement

The company has struggled with profitability, showing consistent net losses in recent years, including a significant net loss of $46.36 million in 2024. Revenue growth is stagnant, with a slight decline from 2023 to 2024. Gross profit margins are relatively stable but have not translated into operating profits, as evidenced by negative EBIT and EBITDA margins in 2024. Overall, the income statement reflects challenges in revenue growth and profitability.

Balance Sheet

The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.02 in 2024. Stockholders' equity has decreased over the years, impacting the equity ratio, which remains decent at 83.31% in 2024. The company maintains a strong cash position, with cash and short-term investments exceeding total debt. However, the decline in total assets and stockholders' equity over recent years raises concerns about long-term financial stability.

Cash Flow

The cash flow statement indicates challenges in generating positive cash flows. Operating cash flow was zero in 2024, and the company has recorded negative free cash flow in prior years. The inability to generate positive cash flow from operations is a critical weakness. The lack of capital expenditures in the latest year suggests potential underinvestment in growth opportunities.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	166.42M	185.36M	185.88M	191.50M	209.63M	183.81M
Gross Profit	69.20M	81.86M	81.07M	82.56M	97.42M	89.96M
EBITDA	-18.85M	-12.70M	27.56M	-132.02M	45.58M	-20.71M
Net Income	-31.22M	-46.35M	7.47M	-123.32M	2.36M	-39.69M
Balance Sheet
Total Assets	513.07M	517.59M	605.07M	767.60M	971.33M	757.54M
Cash, Cash Equivalents and Short-Term Investments	146.95M	149.61M	174.08M	173.45M	259.26M	176.60M
Total Debt	11.37M	10.65M	18.00M	31.87M	32.28M	23.24M
Total Liabilities	82.16M	91.10M	113.30M	296.69M	288.49M	110.04M
Stockholders Equity	435.90M	431.15M	492.01M	485.33M	651.12M	636.52M
Cash Flow
Free Cash Flow	-10.46M	-37.31M	-45.51M	-81.53M	-137.09M	-59.42M
Operating Cash Flow	-7.59M	-32.32M	-34.64M	-67.53M	-122.00M	-29.18M
Investing Cash Flow	15.64M	23.42M	44.50M	2.02M	141.67M	-21.66M
Financing Cash Flow	-3.14M	-7.82M	-7.34M	-7.08M	70.09M	-6.59M

Kaisa Health Group Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.09
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:0876, the sentiment is Positive. The current price of 0.09 is below the 20-day moving average (MA) of 0.19, below the 50-day MA of 0.15, and above the 200-day MA of 0.07, indicating a bullish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 56.33 is Neutral, neither overbought nor oversold. The STOCH value of 48.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:0876.

Kaisa Health Group Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1358	74 Outperform	HK$1.90B	6.78	3.76%	7.46%	21.39%	-0.57%
2276	72 Outperform	HK$29.20B	14.57	24.57%	0.63%	13.58%	24.59%
1501	70 Neutral	HK$6.06B	10.07	10.31%	―	14.06%	3.02%
1066	68 Neutral	HK$22.16B	6.33	8.34%	4.58%	0.74%	2.13%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
0876	47 Neutral	HK$983.22M	-2.63	―	―	-8.46%	45.13%

Kaisa Health Group Holdings Limited Corporate Events

Kaisa Health Announces Name Change of External Auditor

Kaisa Health Group Holdings Limited has announced that its external auditor has formally changed its English name from SFAI (HK) CPA Limited to ZSZH (HK) Fuson CPA Limited, with a corresponding change in its Chinese name effective 9 January 2026. The move reflects an administrative rebranding of the audit firm rather than a change of auditor, and signals continuity in the company’s audit and corporate governance framework under the current board and management structure, with no direct operational or strategic impact disclosed for shareholders or other stakeholders.

The most recent analyst rating on (HK:0876) stock is a Hold with a HK$0.07 price target. To see the full list of analyst forecasts on Kaisa Health Group Holdings Limited stock, see the HK:0876 Stock Forecast page.